Brain+ announces results of Extraordinary General Meeting of Shareholders
Copenhagen, Denmark – 2 September 2022 – Brain+ A/S (“Brain+”) [BRAINP], today announced the results of the Extraordinary General Meeting of Shareholders of Brain+ (“EGM”) which was held on 2 September 2022.
The following resolutions, which had been submitted for shareholder approval, have been approved at the EGM of the Company’s shareholders today.
Election of Chairman of the Meeting: Ricki Boye was elected Chairman of the Meeting.
Election of new members of the Board of Directors with immediate effect: The following persons were elected to the Board of Directors of Brain+:
- Anders Härfstrand
- Johan Luthman
- Betül Susamis Unaran
Jonas Nielsen retires from the Board of Directors of Brain+. Following the new additions, Brain+’ Board of Directors will be comprised of Anders Härfstrand, Lars Terney, Johan Luthman, Betül Susamis Unaran, and Hanne Leth Hillman.
Adoption of Remuneration policy: The proposed remuneration policy was adopted.
Contact Information
CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com
About BRAIN+ [BRAINP]
The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through software-as-medicine applications. Brain+ has developed a set of software-as-medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position in the Digital Therapeutics (DTx) space.
